# A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)

> **NCT07455045** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- High Grade Glioma (III or IV)
- Diffuse Midline Glioma (DMG)
- Glioblastoma (GBM)

## Interventions

- **DRUG:** FZ-AD005

## Key facts

- **NCT ID:** NCT07455045
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07455045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07455045, "A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07455045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*